Overview

Tiotropium in the Treatment of the Patients With Chronic Obstructive Pulmonary Disease

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
0
Participant gender:
All
Summary
To collect post-marketing safety and effectiveness information on the use of Tiotropium Inhalation Capsules (18 μg) in patients with chronic obstructive pulmonary disease in daily clinical settings
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Bromides
Tiotropium Bromide
Criteria
Inclusion Criteria:

- Patients with COPD

Exclusion Criteria:

-There is no exclusion criterion, because this post marketing study (PMS) is observational
survey under condition of normal clinical practice